Relay Therapeutics, Inc.
NASDAQ:RLAY
3 (USD) • At close May 9, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|
| Revenue
| 10.007 | 25.546 | 1.381 | 3.029 | 82.654 | 0 | 0 |
| Cost of Revenue
| 5.464 | 5.269 | 4.13 | 3.925 | 3.549 | 2.845 | 2.154 |
| Gross Profit
| 4.543 | 20.277 | -2.749 | -0.896 | 79.105 | -2.845 | -2.154 |
| Gross Profit Ratio
| 0.454 | 0.794 | -1.991 | -0.296 | 0.957 | 0 | 0 |
| Reseach & Development Expenses
| 319.089 | 330.018 | 246.355 | 172.65 | 99.862 | 70.306 | 41.034 |
| General & Administrative Expenses
| 76.592 | 74.95 | 65.978 | 57.386 | 38.588 | 13.742 | 8.855 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 76.592 | 74.95 | 65.978 | 57.386 | 38.588 | 13.742 | 8.855 |
| Other Expenses
| -13.206 | 0 | -0.02 | -0.004 | -0.016 | -0.058 | -0.009 |
| Operating Expenses
| 382.475 | 398.546 | 312.333 | 230.036 | 138.45 | 84.048 | 49.889 |
| Operating Income
| -372.468 | -373 | -299.275 | -364.698 | -55.796 | -84.048 | -49.889 |
| Operating Income Ratio
| -37.221 | -14.601 | -216.709 | -120.402 | -0.675 | 0 | 0 |
| Total Other Income Expenses Net
| 34.76 | 31.027 | 8.766 | 0.826 | 3.384 | 8.743 | 1.104 |
| Income Before Tax
| -337.708 | -341.973 | -290.509 | -363.872 | -52.412 | -75.305 | -48.785 |
| Income Before Tax Ratio
| -33.747 | -13.387 | -210.361 | -120.129 | -0.634 | 0 | 0 |
| Income Tax Expense
| 0 | 0 | -36.25 | 132.936 | -3.4 | -8.801 | 1.104 |
| Net Income
| -337.708 | -341.973 | -254.259 | -496.808 | -49.012 | -66.504 | -48.785 |
| Net Income Ratio
| -33.747 | -13.387 | -184.112 | -164.017 | -0.593 | 0 | 0 |
| EPS
| -2.36 | -2.79 | -2.27 | -5.22 | -1.15 | -15.53 | -19.63 |
| EPS Diluted
| -2.36 | -2.79 | -2.27 | -5.22 | -1.15 | -15.53 | -19.63 |
| EBITDA
| -372.468 | -374.153 | -306.822 | -222.182 | -52.247 | -81.203 | -47.735 |
| EBITDA Ratio
| -37.221 | -14.646 | -222.174 | -73.352 | -0.632 | 0 | 0 |